Ubs Asset Management Americas Inc Supernus Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 107,789 shares of SUPN stock, worth $3.44 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
107,789
Previous 100,020
7.77%
Holding current value
$3.44 Million
Previous $3.62 Million
2.38%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$332 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$197 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$166 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$92.7 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$86.1 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.71B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...